EGFR and adenocarcinoma: (21) suggested that a particularly low BM incidence in cIA disease (0.3%, 2/615) provides evidence that there is no need for staging brain MRI in patients with cIA NSCLC, whereas brain MRI should be considered in stage over cIA disease or EGFR-mutated adenocarcinoma.